CeQur has reported its PaQ insulin delivery device initial study data at the 6th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Paris, France.
The discreet, wearable CE-marked device, which comprises a disposable insulin infuser reservoir attached to a reusable insulin monitor, provides three days of consistent, basal insulin delivery along with on-demand bolus insulin.
The study, which had enrolled 20 patients, was designed to evaluate the ability of people with type 2 diabetes who were on a stable multiple daily insulin injections (MDI) regimen to use PaQ to replace the daily insulin injections required to control the blood sugar.
The company said approximately 50% of insulin-requiring patients do not achieve appropriate glycemic control, which is associated with additional healthcare costs and high risk of disabling complications including diabetic retinopathy, chronic kidney and cardiovascular diseases.
The study endpoints included glycemic control, patient satisfaction and safety.
Medical University of Graz endocrinology and metabolism division member Dr Julia Mader, who presented the data, said; "This study demonstrated that simple infusion with a device such as PaQ is a valid approach for people with type 2 diabetes who are dependent on multiple daily insulin injections."
The study also demonstrated that PaQ safely and effectively delivered patients' insulin requirements with a high level of patient satisfaction and acceptance.
In addition, no severe hypoglycemic events occurred during the study baseline period, or while participants were using the PaQ device.